AbbVie Reports Phase 3 Results for Rinvoq in Juvenile Idiopathic Arthritis

AbbVie today announced Phase 3 trial results for Rinvoq (upadacitinib) in patients with polyarticular juvenile idiopathic arthritis (pJIA). The trial met its primary endpoint, demonstrating a significant reduction in disease activity compared to placebo. These results led to FDA approval of Rinvoq for pJIA, expanding its use to pediatric patients.